Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs

In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications

Year of Publication: 2020
Contained in: Rheumatology international Vol. 40, No. 6 (2020), p. 991-995
All journal articles: Search for all articles in this journal
Language: English
Contributors: Song, Jehun | Author
Kang, Seongmin
Choi, Seung Won
Seo, Kwang Won
Lee, Sunggun
So, Min Wook
Lim, Doo-Ho
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: 2494G1JF75
4QWG6N8QKH
COVID-19
Case Reports
Coronavirus
Disease-modifying antirheumatic drugs
Journal Article
O3J8G9O825
Pneumonia
Rheumatoid arthritis
lopinavir-ritonavir drug combination
Additional Keywords: Antirheumatic Agents
Arthritis, Rheumatoid
China
Coronavirus Infections
Drug Combinations
Female
Humans
Hydroxychloroquine
Immunocompromised Host
Lopinavir
Middle Aged
Pandemics
Pneumonia, Viral
Real-Time Polymerase Chain Reaction
Ritonavir
Treatment Outcome
ISSN: 1437-160X
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 04.05.2020
Date Revised 05.05.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1007/s00296-020-04584-7
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04515nma a2200997 c 4500
001 NLM309838886
003 DE-601
005 20200505215054.0
007 cr uuu---uuuuu
008 200421s2020 000 0 eng d
024 7 |a 10.1007/s00296-020-04584-7  |2 doi 
028 5 2 |a pubmed20n1189.xml 
035 |a (DE-599)NLM32314010 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Song, Jehun 
245 1 0 |a Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 04.05.2020 
500 |a Date Revised 05.05.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications 
611 2 7 |a Case Reports  |2 gnd 
611 2 7 |a Journal Article  |2 gnd 
653 2 |a Antirheumatic Agents  |6 D018501  |a adverse effects  |6 Q000009  |a therapeutic use  |6 Q000627 
653 2 |a Arthritis, Rheumatoid  |6 D001172  |a complications  |6 Q000150  |a drug therapy  |6 Q000188  |a *immunology  |6 Q000276  |a virology  |6 Q000821 
653 2 |a China  |6 D002681 
653 2 |a Coronavirus Infections  |6 D018352  |a complications  |6 Q000150  |a *drug therapy  |6 Q000188 
653 2 |a Drug Combinations  |6 D004338 
653 2 |a Female  |6 D005260 
653 2 |a Humans  |6 D006801 
653 2 |a Hydroxychloroquine  |6 D006886  |a therapeutic use  |6 Q000627 
653 2 |a Immunocompromised Host  |6 D016867 
653 2 |a Lopinavir  |6 D061466  |a *therapeutic use  |6 Q000627 
653 2 |a Middle Aged  |6 D008875 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a complications  |6 Q000150  |a *drug therapy  |6 Q000188 
653 2 |a Real-Time Polymerase Chain Reaction  |6 D060888 
653 2 |a Ritonavir  |6 D019438  |a *therapeutic use  |6 Q000627 
653 2 |a Treatment Outcome  |6 D016896 
655 7 |a COVID-19  |2 gnd 
655 7 |a Coronavirus  |2 gnd 
655 7 |a Disease-modifying antirheumatic drugs  |2 gnd 
655 7 |a Pneumonia  |2 gnd 
655 7 |a Rheumatoid arthritis  |2 gnd 
655 7 |a Antirheumatic Agents  |2 gnd 
655 7 |a Drug Combinations  |2 gnd 
655 7 |a lopinavir-ritonavir drug combination  |2 gnd 
655 7 |a Lopinavir  |2 gnd 
655 7 |a 2494G1JF75  |2 gnd 
655 7 |a Hydroxychloroquine  |2 gnd 
655 7 |a 4QWG6N8QKH  |2 gnd 
655 7 |a Ritonavir  |2 gnd 
655 7 |a O3J8G9O825  |2 gnd 
689 0 0 |A f  |a Case Reports 
689 0 1 |A f  |a Journal Article 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a Coronavirus 
689 1 2 |a Disease-modifying antirheumatic drugs 
689 1 3 |a Pneumonia 
689 1 4 |a Rheumatoid arthritis 
689 1 |5 DE-601 
689 2 0 |a Antirheumatic Agents 
689 2 1 |a Drug Combinations 
689 2 2 |a lopinavir-ritonavir drug combination 
689 2 3 |a Lopinavir 
689 2 4 |A r  |a 2494G1JF75 
689 2 5 |a Hydroxychloroquine 
689 2 6 |A r  |a 4QWG6N8QKH 
689 2 7 |a Ritonavir 
689 2 8 |A r  |a O3J8G9O825 
689 2 |5 DE-601 
700 1 |a Kang, Seongmin 
700 1 |a Choi, Seung Won 
700 1 |a Seo, Kwang Won 
700 1 |a Lee, Sunggun 
700 1 |a So, Min Wook 
700 1 |a Lim, Doo-Ho 
773 0 8 |i in  |t Rheumatology international  |g Vol. 40, No. 6 (2020), p. 991-995  |q 40:6<991-995  |w (DE-601)NLM012644390  |x 1437-160X 
856 4 1 |u http://dx.doi.org/10.1007/s00296-020-04584-7  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 40  |j 2020  |e 6  |b 20  |c 06  |h 991-995